Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
Showing 1 - 25 of >10,000
MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)
Recruiting
- MDS/MPN
- Azacitidine (AZA) with Ruxolitinib
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Apr 17, 2023
Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)
Not yet recruiting
- Untreated Myelodysplastic Syndrome
- Onureg + Venetoclax
-
Angers, France
- +9 more
Mar 13, 2023
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +3 more
Nov 21, 2023
MDS Trial in Hefei (Unrelated Umbilical Cord Blood, Venetoclax, Decetabine)
Recruiting
- Myelodysplastic Syndromes
- Unrelated Umbilical Cord Blood
- +3 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of University of Science and Techn
Oct 27, 2023
MDS Trial in Houston (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2023
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)
Not yet recruiting
- Higher Risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- AMG 176
- Azacitidine
- (no location specified)
Jul 29, 2022
MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Sabatolimab
- +2 more
- (no location specified)
Sep 2, 2022
Acute Myeloid Leukemia, MDS Trial in Rochester, Houston (CTX-712)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Rochester, Minnesota
- +1 more
Feb 15, 2023
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul
Active, not recruiting
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)
Recruiting
- Myelodysplastic Syndromes
- Myeloproliferative Chronic Myelomonocytic Leukemia
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)
Active, not recruiting
- Myelodysplastic Syndromes
- cyclophosphamide, fludarabine, and antithymocyte globulin
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
MDS Trial (Roxadustat in combination with retinoic acid)
Not yet recruiting
- Myelodysplastic Syndromes
- Roxadustat in combination with retinoic acid
- (no location specified)
Aug 26, 2023
MDS Trial (Decitabine/Cedazuridine, Magrolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- (no location specified)
Apr 18, 2023
MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 16, 2023
Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)
Available
- Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
- Relapsed/Refractory Acute Myeloid Leukemia
- Magrolimab
- (no location specified)
Jan 18, 2023
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation
- +2 more
- VEN+AZA+Modified BUCY
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 10, 2023
Low Risk MDS Trial (R906289 Monosodium (R289 Na))
Not yet recruiting
- Low Risk Myelodysplastic Syndromes
- R906289 Monosodium (R289 Na)
- (no location specified)
Jul 22, 2022
High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)
Active, not recruiting
- High Risk Myelodysplastic Syndrome
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022